Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nojomi
 
IRCT20180725040596N2
RCTumifenovir (arbidol)lopinavir/ritonavirCOVID 19 hospitalizedsome concern
50/50 inconclusive

    COVID-19 mild to moderate meta-analysis

    ELACOI (Lopinavir/ritonavir)
     
    NCT04252885
    RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
    35/34 inconclusive
    • inconclusive 84 % increase in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
    • inconclusive 8 % increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).